GRI Bio (GRI Bio) Net Margin % : 0.00% (As of Mar. 2024)

View and export this data going back to 2023. Start your Free Trial

What is GRI Bio Net Margin %?

Net margin is calculated as Net Income divided by its Revenue. GRI Bio's Net Income for the three months ended in Mar. 2024 was $-1.89 Mil. GRI Bio's Revenue for the three months ended in Mar. 2024 was $0.00 Mil. Therefore, GRI Bio's net margin for the quarter that ended in Mar. 2024 was 0.00%.

The historical rank and industry rank for GRI Bio's Net Margin % or its related term are showing as below:

GRI's Net Margin % is not ranked ^*
in the Biotechnology industry.
Industry Median: -148.41
* Ranked among companies with meaningful Net Margin % only.

GRI Bio Net Margin % Historical Data

The historical data trend for GRI Bio's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GRI Bio Net Margin % Chart

GRI Bio Annual Data

Trend

Dec21

Dec22

Dec23

Net Margin %

GRI Bio Quarterly Data
	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Net Margin %	Get a 7-Day Free Trial					-	-	-	-	-

Competitive Comparison of GRI Bio's Net Margin %

For the Biotechnology subindustry, GRI Bio's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

GRI Bio's Net Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, GRI Bio's Net Margin % distribution charts can be found below:

* The bar in red indicates where GRI Bio's Net Margin % falls into.

GRI Bio Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

GRI Bio's Net Margin for the fiscal year that ended in Dec. 2023 is calculated as

Net Margin	=	Net Income (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-13.037	/	0
	=	%

GRI Bio's Net Margin for the quarter that ended in Mar. 2024 is calculated as

Net Margin	=	Net Income (Q: Mar. 2024 )	/	Revenue (Q: Mar. 2024 )
	=	-1.887	/	0
	=	%

GRI Bio (NAS:GRI) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

GRI Bio Net Margin % Related Terms

Thank you for viewing the detailed overview of GRI Bio's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

GRI Bio (GRI Bio) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » GRI Bio Inc (NAS:GRI) » Definitions » Net Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

2223 Avenida De La Playa, Suite 208, La Jolla, CA, USA, 92037

Website

https://www.gribio.com

GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis.

Executives

David Leslie Szekeres	director	C/O REGULUS THERAPEUTICS INC., 3545 JOHN HOPKINS COURT, SUITE 210, SAN DIEGO CA 92121
Roelof Rongen	director	C/O MATINAS BIOPHARMA HOLDINGS, INC., 1545 ROUTE 206 SOUTH, SUITE 302, BEDMINSTER NJ 07921
Camilla V Simpson	director	20 ELAINE AVE., MILL VALLEY CA 94941
Albert Agro	officer: Chief Medical Officer	828 RICHMOND STREET WEST, TORONTO A6 M6J 1C9
Walter Marc Hertz	director, 10 percent owner, officer: Chief Executive Officer	2223 AVIENDA DE LA PLAYA, SUITE 208, LA JOLLA CA 92037
Vipin Chaturvedi	officer: Chief Scientific Officer	2223 AVIENDA DE LA PLAYA, SUITE 208, LA JOLLA CA 92037
Meenu Chhabra	director	C/O VALLON PHARAMCEUTICALS, INC., 100 N 18TH, STREET, SUITE 300, PHILADELPHIA PA 19103
Joseph E Payne	director	10628 SCIENCE CENTER DRIVE, SUITE 200, SAN DIEGO CA 92121
Leanne M. Kelly	officer: Chief Financial Officer	C/O VALLON PHARAMCEUTICALS, INC., 100 N 18TH STREET, SUITE 300, PHILADELPHIA PA 19103
Marella Thorell	director	1226 CHARTER LANE, AMBLER PA 19002
Arcturus Therapeutics Holdings Inc.	10 percent owner	10628 SCIENCE CENTER DRIVE, SUITE 250, SAN DIEGO CA 92121
Penny Toren	officer: SVP, Regul Affairs & Prog Mgmt	C/O VALLON PHARMACEUTICALS, INC., 100 N. 18TH STREET, SUITE 300, PHILADELPHIA PA 19103
Ofir Levi	director	C/O VALLON PHARMACEUTICALS, INC., 100 N. 18TH STREET, SUITE 300, PHILADELPHIA PA 19103
Richard Ammer	director, 10 percent owner	C/O VALLON PHARMACEUTICALS, INC., 100 N. 18TH STREET, SUITE 300, PHILADELPHIA PA 19103
Pharma Gmbh Salmon	10 percent owner	SANKT-JACOBS-STRASSE 90, CH-9002, BASEL V8 4052